All minutes from the EUnetHTA/EMA meetings are now available
Please find below a list of links to all minutes from all six meetings between EUnetHTA and EMA since the start of the collaboration in 2010. EUnetHTA-EMA face-to-face meeting summary, 11 February, 2010, London UK EUnetHTA-EMA face-to-face meeting summary, 3 June, 2010, London UK EUnetHTA-EMA face-to-face meeting summary, 7 March, 2011, Diemen Netherlands EUnetHTA-EMA face-to-face meeting summary, […]
EMA and EUnetHTA review progress of cooperation
European Medicines Agency (EMA) and EUnetHTA met in London on 14 May 2013 to review the progress of the cooperation. Please find the joint press release here
[CLOSED] Public consultation of the Draft Project Plan on “Renal sympathetic denervation (Symplicity®)”
Public consultation of the Draft Project Plan on “Renal sympathetic denervation (Symplicity®) for the treatment of resistant arterial hypertension”. We are pleased to announce that as of today the Draft Project Plan on “Renal sympathetic denervation (Symplicity®) for the treatment of resistant arterial hypertension”, produced within WP5 Strand B, has entered the public consultation phase. […]
HTA 2.0 Europe: teaming up for value
Mark your calendars for the next EUnetHTA Conference in Rome, October 2014! More information coming soon……
EUnetHTA JA2 3-year Work Plan is available
The EUnetHTA Plenary Assembly has approved the EUnetHTA JA2 3-year Work Plan. The document lays out details and timelines of the activities planned in each of the eight Work Packages of the EUnetHTA JA2 (2012-2015). The plan may be adjusted prospectively at the end of each of the project year. The 3-year Work Plan is […]
CLOSED:Public consultation of the Draft Project Plan on “Duodenal-jejunal bypass sleeve (Endobarrier®) for the treatment of obesity”
This consultation took place between 21 March and 4 April 2013, and is now closed. The aim of the Draft Project Plan is to provide an overview on the planned processes, the scope, the scientific methods and the time-schedule for compiling a pilot rapid assessment on the technology mentioned above. Further, the pilot rapid assessment […]
Response to Public consultation of draft Project Plan on Endobarrier is available
The response received on the Public consultation of the draft Project Plan on Endobarrier is now available. The draft Project Plan on “Duodenal-jejunal bypass sleeve (Endobarrier®) for the treatment of obesity” was open to public consultation between 21 March and 4 April 2013. The comments and response to this public consultation is now available here.
This consultation took place between 21 March and 4 April 2013, and is now closed. The aim of the Draft Project Plan is to provide an overview on the planned processes, the scope, the scientific methods and the time-schedule for compiling a pilot rapid assessment on the technology mentioned above. Further, the pilot rapid assessment (partly or as a whole) will be translated into national/local reports by participating WP5 members. The processing of the comments: The submissions will be processed by the WP5 Co- Lead Partner, LBI-HTA. If responders wish to modify their submission, they should contact the LBI-HTA at the e-mail address given within the timeframe of the public consultation. LBI-HTA will not share responders’ data with third parties for direct marketing. All comments will be formally responded to in a combined document that will be posted on the EUnetHTA website within a month. This document will also contain the contact information of all the organisations that properly submitted contributions (unless the author has explicitly opposed publication of their contribution or the contributions do not address the draft Project Plan or contain complaints against institutions, personal accusations, irrelevant or offensive statements or material). The name of the author, his affiliation and date of the submission’s receipt will be disclosed when the contribution is made public. No action will be taken upon receipt of late comments. You should receive a response to your email with comments as a confirmation that your comments have been received. If you do not receive this acknowledgement, please contact (anna.nachtnebel@hta.lbg.ac.at) to ensure your comments have been safely received. A reply to acknowledge receipt of submission is foreseen (see point 4) however no further individual reply will be made. The final pilot rapid assessment will be published on the EUnetHTA website after its completion.
In Joint Action 2, EUnetHTA will continue to address methodological challenges of HTA. Methodology in focus – EUnetHTA guidelines In Joint Action 2, EUnetHTA will continue to address methodological challenges of HTA. In Joint Action 1 (2010-2012) EUnetHTA has produced nine guidelines on methodological issues associated with relative effectiveness assessment of pharmaceuticals (REA) (1). In […]
[CLOSED] Public consultation of the Policy for the HTA Core Model® and core HTA information
The policy for the HTA Core Model and core HTA information – produced earlier within EUnetHTA Joint Action 2010-2012 – will be reviewed by WP8 of EUnetHTA Joint Action 2 during spring 2013. We are happy to announce that as of today, the policy is available for public feedback, which will be used in the […]
The JA1 Core HTAs are available
The two very first full Core HTAs are publicly available on the HTA Core Model® website. These are Abdominal Aorta Aneurysm Screening (AAA) and Prognostic tests for breast cancer recurrence (PTBCR). 1) Population-based systematic abdominal aortic aneurysm (AAA) screening This includes assessment of a population-based screening of Abdominal Aorta Aneurysm (AAA) compared to not doing […]
